Novel oral cephalosporins

Bibliography

• Cephalosporins and related compounds. In: Drug Facts and Comparisons. Olin BR (Ed.) Facts and Comparisons, Inc., St Louis, USA 1996:335g–3381.
   Google Scholar
• DARVILLE T, YAMAUCHI T: The cephalosporin antibi-otics. Pediatr. Rev. (1994) 15(2):54–62.
   PubMedGoogle Scholar
• •
   Google Scholar
• LIPUMA JJ, STULL TL: Antibacterial agents in pediatrics.Infect. Dis. Clin. North Am. (1995) 9:561–574.
   PubMed Web of Science ®Google Scholar
• SMITH GH: Oral cephalosporins in perspective. DICP (1990) 24:45–51.
   PubMedGoogle Scholar
• JONES RN: Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.. Pediatr. Infect. Dis. J. (1993) 12 (Suppl 6):S37–S44.
   Google Scholar
• BAUERNFEIND A, JUNGWIRTH R: Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection (1991) 19(5):353–362.
   PubMed Web of Science ®Google Scholar
• DEBBIA EA, MARCHESE A, PESCE A, SAVERINO D, SCHITO GC: Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens. J. Chemother. (1992) 4:131–144.
   PubMed Web of Science ®Google Scholar
• LEGGETT NJ, CARAVAGGIO C, RYBAK MJ: Cefixime. DICP (1990) 24:489–495.
   PubMedGoogle Scholar
• GUAY DR: Ceftibuten: a new expanded-spectrum oral cephalosporin. Ann. Pharmacother. (1997) 31(9):1022–1033.
   PubMed Web of Science ®Google Scholar
• LIU YC, HUANG WK, CHENG DL: Antibacterial activity of cefpodoxime in vitro. Chemotherapy (1997) 43 (1):21–26.
   PubMed Web of Science ®Google Scholar
• VERHAEGEN J, VERBIST L: In-vitro activity of 21 6-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. (1998) 41:381–385.
   PubMed Web of Science ®Google Scholar
• KLESEL N, ADAM F, ISERT D et al.: RU 29246, the active compound of the cephalosporin prodrug-ester HR 916. III. Pharmacokinetic properties and antibacterial activity in vivo. J. Antibiot. (Tokyo) (1992) 45 (6):922–931.
   Google Scholar
• SPECIALE A, CACCAMO F, BLANDINO G, GIACCHI GT, ALEO G, NICOLETTI G: Cefetamet pivoxil: comparable evaluation with other orally available antibiotics against selected species of respiratory pathogens. Chemotherapy (1996) 42 (1) :1–10.
   PubMed Web of Science ®Google Scholar
• SIMON C: In vitro activity of Ro 15-8074 and Ro 19-5247in comparison to cefaclor and cefalexin. Infection (1987) 15(2):122–124.
   PubMed Web of Science ®Google Scholar
• ROZGONYI F, PAPP-FALUSI E, VARGA J, ROZGONYI-SZITHA K: In-vitro activity of cefetamet (Ro 15-8074) compared with other oral agents. J. Antimicrob. Chemother. (1989) 24(4):539–546.
   PubMed Web of Science ®Google Scholar
• JONES RN, BIEDENBACH DJ, CROCO MA, BARRETT MS: Invitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumo-niae. Diagn. Microbiol. Infect. Dis. (1998) 31:573–578.
   PubMed Web of Science ®Google Scholar
• IWAI N, NAKAMURA H, MIYAZU M, WATANABE Y: Pharmacokinetic, bacteriological and clinical evalua-tion of cefditoren pivoxil in pediatrics. Jpn. J. Antibiot. (1994) 47(2):181–194.
   PubMedGoogle Scholar
• FUKUOKA T, KAWADA H, KITAYAMA A et al.: Efficacy ofCS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice. Antimicrob. Agents Chemother. (1998) 42(1):23–27.
   PubMed Web of Science ®Google Scholar
• SCRIVER SR, WILLEY BM, LOW DE, SIMOR AE: Compara-tive in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, Gram-negative bacilli and respiratory tract pathogens. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11(7)646–652.
   Google Scholar
• SCRIBNER RK, MARKS MI, FINKHOUSE BD: In vitro activity of BMY-28100 against common isolates from pediatric infections. Antimicrob. Agents Chemother. (1987) 31 (4):630–631.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN EJ, NESBIT CA, CITRON DM: Comparative in vitro activities of azithromycin, Bay y 3118, levofloxa-cin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob. Agents Chemother. (19 9 5) 39(5) :1097–1100.
   Google Scholar
• BARRIERE SL: Review of in vitro activity, pharmacoki-netic characteristics, safety, and clinical efficacy of cefprozil, a new oral cephalosporin. Ann. Pharmaco-ther. (1993) 2 7 (9):1082–1089.
   Google Scholar
• KIMURA Y. YOSHIDA I. HIGASHIYAMA I. NAGANO K. SASAKI S: Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents. Jpn. j Chemother. (1998) 46(9):324–342.
   Google Scholar
• NEU-HC, GU-J-W, FANG-W, CHIN-N-X: In vitro activity and susceptibility to hydrolysis of S-1006. Antimicrob. Agents Chemother. (1992) 36(6):1336–1341.
   PubMed Web of Science ®Google Scholar
• MIZOJIRI K, FUTAGUCHI S, NORIKURA R et al: Disposi-tion of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloy1-14C]S-1108 in rats and dogs. Antimicrob. Agents Chemother. (1995) 39(7):1445–1453.
   PubMed Web of Science ®Google Scholar
• BERGAN T, DA FONSECA J: Antibacterial activity of cefcanel. Chemotherapy (1993) 39 (2):96–104.
   PubMed Web of Science ®Google Scholar
• CHIN NX, GU JW, NEU HC: In vitro activity of cefcanel versus other oral cephalosporins. Eur. J. Clin. Microbiol. Infect. Dis. (1991) 10(8):676–682.
   PubMed Web of Science ®Google Scholar
• OBANA Y, HASHIZUME H, YOSHIMI A, NISHINO T: Invitro and in vivo antibacterial activity of KY-109, a new orally active cephalosporin. J. Antibiot. (Tokyo) (1988) 41(7):949–958.
   PubMed Web of Science ®Google Scholar
• TSUJI M, ISHII Y, OHNO A, MIYAZAKI S, YAMAGUCHI K:In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin. Antimicrob. Agents Chemother. (1995) 39(10:2544–2551.
   PubMed Web of Science ®Google Scholar
• ADAMS RG, BRAIN E.G., BRANCH CL et al: Structure-activity relationships within a series of C(7)-substitut-e doxyimino cep ha lo spor ins containing the C(3)-methylaminopyridiniumthiomethyl substituent. Synthesis and biological properties of BRL 57342 and some close analogues. J. Antibiot. (Tokyo) (1995) 48(5):417–424.
   Google Scholar
• NEGI S, YAMANAKA M, SUGIYAMA I et al: Studies onorally active cephalosporins. I. Synthesis and structure-activity relationships of new 3-substituted carbamoyloxymethyl cephalosporins. J. Antibiot. (Tokyo) (1994) 47(12):1507–1525.
   Google Scholar
• MIKAMO H, SATOH M, KAI J, SATO Y, HAYASAKI Y, TAMAYA T: In vitro bactericidal activities of a new oral cephalosporin, E1100, and morphologic changes on Escherichia colt'. Chemotherapy (1999) 45(4):249–252.
   PubMed Web of Science ®Google Scholar
• MIKAMO H, SATO Y, HAYASAKI Y, KAWAZOE K, TAMAYA T: In vitro activities of E1101, a novel oral cephalosporin, against bacteria causing infections in obstetric and gynecological patients. Chemotherapy (1998) 44(5)328–330.
   Google Scholar
• WATANABE Y, HATANO K, MATSUMOTO Y et al.: In vitroantibacterial activity of FK041, a new orally active cephalosporin. J. Antibiot. (Tokyo) (1999) 52 (7):649–659.
   PubMed Web of Science ®Google Scholar
• TAWARA S, HATANO K, WAKAI Y et al: In vivo antibacte-rial activity of FK041, a new orally active cephalo-sporin. j Antibiot. (Tokyo) (1999) 52(7):660–665.
   PubMed Web of Science ®Google Scholar
• KASAI M, HATANO S, KITAGAWA M et al: AS-924, a novel bifunctional prodrug of ceftizoxime. J. Antibiot. (Tokyo) (1999) 52(5):491–500.
   PubMed Web of Science ®Google Scholar
• KLEPSER ME, MARANGOS MN, PATEL KB, NICOLAU DP,QUINTILIANI R, NIGHTINGALE CH: Clinical pharma-cokinetics of newer cephalosporins. Gun. Pharma-cokinet. (1995) 28(5):361–384.
   Google Scholar
• KNEER J: Pharmacokinetic properties of new oral cephalosporins. Méd. Mal. Infect. (1992) 22:556–564.
   Web of Science ®Google Scholar
• LODE H, FASSBENDER M, SCHABERG T et al.: Compara-tive pharmacokinetics of the new oral cephalo-sporins. Drugs (1994) 47 (Suppl. 3):10–19.
   Google Scholar
• NIX DE, SYMONDS WT, HYATT JM et al.: Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. Pharmacotherapy (1997) 17 (1) :121–125.
   PubMed Web of Science ®Google Scholar
• FUJITOMO H, NAGAOKA T, NISHINO I, UMEDA T: Determination of a new oral cephalosporin, S-1090, in human plasma and urine by direct injection high-performance liquid chromatography with ultraviolet detection and column switching. J. Chroma-togr. B. Biomed. Sci. Appl. (1999) 728(0:125–131.
   PubMed Web of Science ®Google Scholar
• MEALY N, CASTANER J: S-1090. Drugs Future (1996) 21(3)254–257.
   Google Scholar
• EDWALL B, ARVIDSSON A, LAKE-BAKAAR D, LANBECK-VALLEN K, YISAK W: Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. Drug Metab. Dispos. (1993) 21(0:171–177.
   PubMed Web of Science ®Google Scholar
• LI JT, HOU F, LU H, LI TY, LI H: Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers. Drugs Exp. Clin. Res. (1997) 23(5-6):145–150.
   PubMedGoogle Scholar
• NAKASHIMA M, UEMATSU T, OGUMA T et al.: Phase Iclinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. Antimicrob. Agents Chemother. (1992) 36(4)762–768.
   Google Scholar
• TOTSUKA K, SHIMIZU K, KONISHI M, YAMAMOTO S: Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Antimicrob. Agents Chemother. (1992) 36(4)757–761.
   Google Scholar
• BERGOGNE-BEREZIN E: Cefpodoxime proxetil in upper respiratory tract infections. Drugs (1991) 42 (Suppl. 3):25–33.
   Google Scholar
• MULLER-SERIEYS C, BANCAL C, DOMBRET MC et al: Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. Antimicrob. Agents Chemother. (1992) 36(102099–2103.
   Web of Science ®Google Scholar
• BALDWIN DR, WISER, ANDREWS JM, HONEYBOURNE D:Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. J. Antimicrob. Chemother. (1992) 30(1):67–71.
   PubMed Web of Science ®Google Scholar
• BALDWIN DR, ANDREWS JM, ASHBY JP, WISE R, HONEYBOURNE D: Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax (1990) 45(5):401–402.
   PubMed Web of Science ®Google Scholar
• GRELLET J, COURAUD L, SAUX MC, ROCHE G: Diffusionpulmonaire du cefixime chez l'homme. Presse Méd. (1989) 18(32):1589–1592.
   PubMed Web of Science ®Google Scholar
• BLOUIN RA, STOECKEL K: Cefetamet pivoxil clinicalpharmacokinetics. Gun. Pharmacokinet. (1993) 25(3):172–188.
   PubMed Web of Science ®Google Scholar
• SCAGLIONE F, COGO R, RASCHI S et al: Studio clinico efarmacocinetico di cefetamet pivoxil in confronto con il cefixime nella bronchite cronica riacutizzata. Antibi-oticoterapia per la pratica (1995) 3(2)92–97.
   Google Scholar
• KRUMPE P, LIN CC, RADWANSKI E, CAYEN MN, AFFRIMEMB: The penetration of ceftibuten into the respiratory tract. Chest (1999) 116(2):369–374.
   PubMed Web of Science ®Google Scholar
• KUMAZAWA J, SHIBA K, KIMURA Y, SASAKI S: The distri-bution of S-1090, a new oral cephalosporin, to various human tissues following oral administration. kaac 35th San Francisco USA (1995) Abstract F37.
   Google Scholar
• SCHENTAG JJ, BIRMINGHAM MC, PALADINO JA et al.: Innosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determi-nant of successful clinical outcome, and a better means of avoiding resistance. Semin. Respir. Infect. (1997) 12(4):278–293.
   PubMedGoogle Scholar
• CRAIG WA: Outpatient parenteral antibiotic therapy.Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Selecting the antibi-otic. Selecting the antibiotic. Hosp. Pract. (1993) 28 (Suppl. 1):16–20.
   Google Scholar
• NIX DE, SCHENTAG JJ: Role of pharmacokinetics andpharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Diagn. Microbiol. Infect. Dis. (1995) 22\(Suppl. 1–2):71–76.
   Google Scholar
• LEWIS RE, KLEPSER ME: Update on clindamycin: newpharmacokinetic and pharmacodynamic data. Infections in Medicine (1998) 17:726–731.
   Google Scholar
• CAZZOLA M, MATERA MG, DONNER CF: Pharmacoki-netics and pharmacodynamics of newer oral cephalo-sporins: implication for treatment of community-acquired lower respiratory tract infections. Clin. Drug Invest. (1998) 16:335–346.
   PubMed Web of Science ®Google Scholar
• CARS 0: Efficacy of beta-lactam antibiotics: integrationof pharmacokinetics and pharmacodynamics. Diagn. Microbiol. Infect. Dis. (1997) 27(1):29–34.
   PubMed Web of Science ®Google Scholar
• STOECKEL K, HAYTON WL, EDWARDS DJ: Clinical pharmacokinetics of oral cephalosporins. In: Oral Cephalosporins Antibiotic Chemotherapy, Moellering RC Jr, (Eds.) Basel Karger (1995) 47:34–71.
   Google Scholar
• CRAIG WA: Interrelationship between pharmacoki-netics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. (1995) 22(1-2):89–96.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, MATERA MG: Interrelationship betweenpharmacokinetics and pharmacodynamics in the design of dosage regimens for treating acute exacerba-tions of chronic bronchitis. Respir. Merl. (1998) 92 (7):895–901.
   PubMed Web of Science ®Google Scholar
• BRUMFITT W, HAMILTON-MILLER JM: Cefaclor into the millennium. J. Chemother. (1999) 11 (3):163–178.
   PubMed Web of Science ®Google Scholar
• OMIDVARI K, DE BOISBLANC BP, KARAM G, NELSON S, HAPONIK E, SUMMER W: Early transition to oral antibi-otic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir. Merl. (1998) 92(8):1032–1039.
   PubMed Web of Science ®Google Scholar
• RIMMER DM: Oral cephalosporins for use in a parenteral-to-oral switch programme. Infection (1995) 23 (Suppl. 2):S87–S90.
   Google Scholar
• MAC GOWAN AP, BOWKER KE: Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. J. Infect. (1998) 37 (Suppl. 1):30–36.
   Google Scholar
• RAMIREZ JA, SRINATH L, AHKEE S, HUANG A, RAFF MJ:Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. (1995) 155(12):1273–1276. Mario Cazzola
   Google Scholar